Lipidomics reveals that sustained SREBP-1-dependent lipogenesis is a key mediator of gefitinib-acquired resistance in EGFR-mutant lung cancer
Authors:
Open Access
- 13 November 2021
- journal article
- research article
- Published by Springer Nature in Cell Death Discovery
- Vol. 7 (1) , 1-9
Abstract
Patients with EGFR mutations in non-small cell lung cancer (NSCLC) have been greatly benefited from gefitinib, however, the therapeutic has failed due to the presence of acquired resistance. In this study, we show that gefitinib significantly induces downregulation of Sterol Regulator Element Binding (SREBP1) in therapy-sensitive cells. However, this was not observed in EGFR mutant NSCLC cells with acquired resistance. Lipidomics analysis showed that gefitinib could differently change the proportion of saturated phospholipids and unsaturated phospholipids in gefitinib-sensitive and acquired-resistant cells. Besides, levels of ROS and MDA were increased upon SREBP1 inhibition and even more upon gefitinib treatment. Importantly, inhibition of SREBP1 sensitizes EGFR-mutant therapy-resistant NSCLC to gefitinib both in vitro and in vivo models. These data suggest that sustained de novo lipogenesis through the maintenance of active SRBEP-1 is a key feature of acquired resistance to gefitinib in EGFR mutant lung cancer. Taken together, targeting SREBP1-induced lipogenesis is a promising approach to overcome acquired resistance to gefitinib in EGFR-mutant lung cancer.Keywords
Funding Information
- National Natural Science Foundation of China (81573658)
- Guangdong Provincial Key Laboratory of Construction Foundation
This publication has 45 references indexed in Scilit:
- Lipid Metabolism, Apoptosis and Cancer TherapyInternational Journal of Molecular Sciences, 2015
- Fatostatin Displays High Antitumor Activity in Prostate Cancer by Blocking SREBP-Regulated Metabolic Pathways and Androgen Receptor SignalingMolecular Cancer Therapeutics, 2014
- Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-NonenalOxidative Medicine and Cellular Longevity, 2014
- Cellular Fatty Acid Metabolism and CancerCell Metabolism, 2013
- Influence of Phospholipid Species on Membrane Fluidity: A Meta-analysis for a Novel Phospholipid Fluidity IndexThe Journal of Membrane Biology, 2011
- EGFR Mutations and Lung CancerAnnual Review of Pathology: Mechanisms of Disease, 2011
- De novo Lipogenesis Protects Cancer Cells from Free Radicals and Chemotherapeutics by Promoting Membrane Lipid SaturationCancer Research, 2010
- The Kennedy pathway—De novo synthesis of phosphatidylethanolamine and phosphatidylcholineIUBMB Life, 2010
- The Kennedy pathway—De novo synthesis of phosphatidylethanolamine and phosphatidylcholineIUBMB Life, 2010
- Chemical Inhibition of Acetyl-CoA Carboxylase Induces Growth Arrest and Cytotoxicity Selectively in Cancer CellsCancer Research, 2007